Spring Discovery is a biotechnology company that develops drugs to treat diseases caused by protein misfolding. The company's proprietary platform uses machine learning algorithms to identify small molecules that can stabilize proteins and prevent them from misfolding. Spring Discovery's lead drug candidate is SD-016, which is being developed to treat transthyretin amyloidosis, a rare and fatal disease caused by the misfolding of the transthyretin protein. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.